接受免疫抑制治疗的肾脏病患儿SARS-CoV-2感染严重程度
回顾性分析40例住院肾脏病患儿,免疫抑制组11例、非免疫抑制组29例。免疫抑制组无重型及危重型,非免疫抑制组有重型15例、危重型1例;免疫抑制组更易表现为无症状或轻型,且细胞因子IL-6、干扰素-α、干扰素-γ水平更低。
要点
- 免疫抑制组无重型及危重型患儿,非免疫抑制组重型15例、危重型1例。
- 免疫抑制组更可能无症状或轻型,重型、细胞因子风暴、发热、咳嗽风险较低。
- 免疫抑制组IL-6、干扰素-α、干扰素-γ水平均低于非免疫抑制组。
核心结论
- 罹患肾脏基础疾病并接受适当免疫抑制治疗的患儿可能通过抑制细胞因子表达水平而减轻新冠病毒感染的病情。
研究设计与样本
- 回顾性分析2022年12月至2023年2月在联勤保障部队第九〇〇医院确诊新冠病毒感染的40例住院患儿临床资料。
- 依据新冠病毒感染前是否存在免疫抑制状态分为免疫抑制组11例和非免疫抑制组29例。
- 采用独立样本t检验、Mann-Whitney U检验和χ²检验比较两组临床基线特征和实验室数据等。
主要发现
- 免疫抑制组年龄13(8,14)岁,男9例、女2例;非免疫抑制组年龄2(1,4)岁,男15例、女14例。
- 免疫抑制组无症状感染2例、轻型8例、普通型1例,无重型及危重型;非免疫抑制组轻型8例、普通型5例、重型15例、危重型1例,无无症状感染。
- 免疫抑制组基础疾病包括肾病综合征6例、IgA血管炎肾炎2例、狼疮性肾炎1例、肾移植术后1例、肾衰竭1例,TIS为(3.6±1.4)分。
- 免疫抑制组IL-6、干扰素-α、干扰素-γ水平均低于非免疫抑制组(Z=2.23、2.51、2.92,均P<0.05)。
关键数值与推荐
- 与非免疫抑制组相比,免疫抑制组更可能表现为无症状感染和轻型,重型、细胞因子风暴、发热、咳嗽风险较低,乏力风险较高(OR=1.22、2.66、0.48、0.12、0.12、0.13、1.22,95%CI 0.93~1.62、0.99~7.15、0.33~0.70、0.03~0.57、0.03~0.57、0.03~0.65、0.93~1.62,均P<0.05)。
临床怎么用
- 对接受适当免疫抑制治疗的肾脏病患儿,感染新冠病毒后病情可能较轻,但仍需关注乏力表现。
- 临床可参考细胞因子IL-6、干扰素-α、干扰素-γ水平评估病情严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the impact of immunosuppressive therapy on the severity of SARS-CoV-2 infection and cytokine levels in pediatric patients with kidney diseases. Methods: A retrospective analysis was conducted on the clinical data of 40 hospitalized pediatric patients who were diagnosed with SARS-CoV-2 infection at the 900th Hospital of PLA Joint Logistic Support Force from December 2022 to February 2023. Based on their immunosuppressive status prior to SARS-CoV-2 infection, these patients were categorized into immunosuppressive group and non-immunosuppressive group. Independent sample t-tests, Mann-Whitney U tests, and χ² test were employed to compare the clinical baseline characteristics and laboratory data, the severity of SARS-CoV-2 infection, and the levels of cytokines between the 2 groups. Results: Among the 40 patients, 11 were in the immunosuppressive group (aged 13 (8, 14) years, 9 males and 2 females) and 29 in the non-immunosuppressive group (aged 2 (1, 4) years, 15 males and 14 females). In the immunosuppressive group, 2 were asymptomatic cases, 8 were mild cases, and 1 was moderate case, and there was no severe or critical cases. In the non-immunosuppressive group, 8 were mild cases, 5 were moderate, 15 were severe cases, 1 was critical case, and no asymptomatic cases. The underlying diseases in the immunosuppressive group included nephrotic syndrome (6 cases), IgA vasculitis nephritis (2 cases), lupus nephritis (1 case), post-renal transplantation (1 case), and renal failure (1 case), with a mean total immunosuppression score (TIS) of (3.6±1.4) points. In the non-immunosuppressive group, 2 patients had a history of epilepsy, and the remaining 27 cases had no underlying conditions, all with TIS scores of 0. Compared to the children in the non-immunosuppressive group, those in the immunosuppressive group were more likely to exhibit asymptomatic or mild infection, with lower risks of severe disease, cytokine storm, fever, and cough, but a higher risk of fatigue (OR=1.22, 2.66, 0.48, 0.12, 0.12, 0.13, 1.22; 95%CI 0.93-1.62, 0.99-7.15, 0.33-0.70, 0.03-0.57, 0.03-0.57, 0.03-0.65, 0.93-1.62; all P<0.05). The levels of cytokine IL-6, interferon-α and interferon-γ in the immunosuppressive group were all lower than those in the non-immunosuppressive group (Z=2.23, 2.51, 2.92, respectively; all P<0.05). Conclusion: Pediatric patients with kidney diseases receiving appropriate immunosuppressive therapy may mitigate the severity of SARS-CoV-2 infection by suppressing the expression of cytokines. 目的: 探讨免疫抑制治疗对肾脏病患儿感染新型冠状病毒(以下简称新冠病毒)后病情严重程度及细胞因子水平的影响。 方法: 回顾性分析2022年12月至2023年2月在联勤保障部队第九〇〇医院确诊新冠病毒感染的40例住院患儿一般情况、临床症状、免疫抑制剂使用情况等临床资料,依据新冠病毒感染前是否存在免疫抑制状态分为免疫抑制组和非免疫抑制组,采用独立样本t检验、Mann-Whitney U检验和χ²检验比较两组患儿临床基线特征和实验室数据等,评估新冠病情严重程度和细胞因子水平。 结果: 40例患儿中免疫抑制组11例[年龄13(8,14)岁,男9例、女2例]、非免疫抑制组29例[年龄2(1,4)岁,男15例、女14例]。免疫抑制组中新冠病毒无症状感染2例、轻型8例、普通型1例,没有重型及危重型患儿;非免疫抑制组中轻型8例、普通型5例、重型15例、危重型1例,没有无症状感染患儿。免疫抑制组患儿基础疾病包括肾病综合征6例、IgA血管炎肾炎2例、狼疮性肾炎1例、肾移植术后1例、肾衰竭1例,总免疫抑制评分(TIS)为(3.6±1.4)分;非免疫抑制组2例患儿有癫痫病史,其余27例无基础疾病,TIS评分均为0分。与非免疫抑制组患儿相比,免疫抑制组患儿感染新冠病毒后更可能表现为无症状感染和轻型,表现为重型、发生细胞因子风暴、伴发热、伴咳嗽的风险均较低,出现乏力表现的风险较高(OR=1.22、2.66、0.48、0.12、0.12、0.13、1.22,95%CI 0.93~1.62、0.99~7.15、0.33~0.70、0.03~0.57、0.03~0.57、0.03~0.65、0.93~1.62,均P<0.05)。免疫抑制组白细胞介素6、干扰素α和γ水平均低于非免疫抑制组(Z=2.23、2.51、2.92,均P<0.05)。 结论: 罹患肾脏基础疾病并接受适当免疫抑制治疗的患儿可能通过抑制细胞因子表达水平而减轻新冠病毒感染的病情。.
引用
- Zhang YF, Yang HH, Huang J, et al. [Severity of SARS-CoV-2 infection in children with kidney disease undergoing immunosuppressive therapy]. Zhonghua Er Ke Za Zhi. 2025. PMID: 40240020. doi:10.3760/cma.j.cn112140-20241111-00813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。